The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
Megan Melody, MD, is an assistant professor at the University of South Florida and lymphoma and CAR T-cell therapy specialist at Tampa General Hospital Cancer Institute. Here’s what she’s looking forward to when it comes to Hodgkin lymphoma and mantle cell lymphoma research at the meeting.
This talk will explore the rationale behind the use of checkpoint blockade as part of upfront therapy and put these recent results into broader context. The talk will also explore whether patients with early-stage HL should be considered for these novel approaches.
I am honored to step into the role as Deputy Director for the Society of Hematologic Oncology (SOHO). Having collaborated with the SOHO team for many years behind the scenes, I am deeply grateful for the opportunity to serve as part of the staff. With over 20 years of experience leading a nonprofit medical education company, I bring expertise in nonprofit management, instructional design, and adult learning principles. My goal is to leverage this experience to enhance SOHO’s programs, ensuring our education empowers clinicians to deliver exceptional patient care.
A study presented by Saad Usmani, MD, MBA, of the Memorial Sloan Kettering Cancer Center, as part of the SOHO 2025 Annual Meeting, showed that the combination of daratumumab, bortezomib, lenalidomide, and dexamethasone (D-VRd) improved outcomes in newly diagnosed, transplant-ineligible patients with multiple myeloma (MM), regardless of cytogenetic risk.
Results from the phase 1/2 CA057-003 study showed early efficacy and safety with the addition of mezigdomide to novel combinations for relapsed or refractory multiple myeloma (MM). The study was […]
The phase 3 MagnetisMM-6 study showed a manageable safety profile and high response rates in transplant-ineligible, newly diagnosed multiple myeloma (MM) patients treated with the combination of elranatamab, daratumumab, and lenalidomide.
Ongoing results from the DREAMM-8 trial reinforced the clinically meaningful progression-free survival (PFS) benefit of belantamab mafodotin, pomalidomide, and dexamethasone (BPd) versus pomalidomide, bortezomib, and dexamethasone (PVd) in relapsed or […]
This is a special year, as SOHO has surpassed the 10,000-member milestone, which is incredible considering the society is just over 10 years old.
“I think we’re poised to develop experimental models through genome editing and other approaches,” Dr. Mullighan said. “We’re also using our experience from understanding genetic approaches to look at newer approaches to context of treatment and drug development, including immunotherapies and targeted protein degradation.”
The addition of daratumumab to bortezomib, lenalidomide, and dexamethasone (D-VRd) improved outcomes in patients with newly diagnosed multiple myeloma (MM) compared with VRd alone.
